Click to view this email in a browser

April 24, 2012
Currents in Cell Medicine
Latest News and Research from the ICMS
Volume 2, Number 4

4th Annual International Congress for Regenerative and Cell-Based Medicine

On May 3rd, 2012, the global cell-medicine community will come together in Hollywood, Florida for the 4th Annual International Congress for Regenerative and Cell-Based Medicine

Lectures will cover a variety of therapeutic areas, from neurological to auto-immune disorders, cell banking, orthopedics, cardiac and wound care and will cover the clinical application of adipose, bone marrow and PRP. There is no other meeting that will be as focused on the point-of-care use of stem cells as this. Join us.


For a full agenda, a complete list of faculty, and additional information about the conference, please visit the ICMS website


Register today, use registration code ICMS, and join us in Hollywood on May 3rd.


News from the ICMS

Executive Board of the International Cellular Medicine Society has read with keen interest the editorial written by the former commissioner of the Food and Drug Administration (FDA) regarding the regulatory conundrum facing Regenerative Medicine in the US, particularly when using a patient’s own cells. 

4th International Congress

Full Agenda

Bone Marrow Derived Stem Cells and Multiple Sclerosis, Saud Ahmed Sadiq, M.D.


Stem Cell Treatment in Neurological Disease, Augusto Brazzini, M.D. 


Platelet Rich Plasma, Ariel Luksenburg Wiernik, M.D.


Clinical Results from Autologous Stromal Vascular Fraction (SVF) Treatment of Autoimmune Conditions,  Neil H. Riordan, Ph.D. 


Stem Cell Viability and Different Anesthetics and the Optimization of G-CFS Use, as it Relates to Stem Cell Induction, Alan A. Kadish, N.M.D. 


Stem Cells and Cardiology, Warren Sherman, M.D.


Emerging Trends in Cell Banking, Julie Allickson, PhD 


From Bench to Bedside: Clinical Translation of Innovative Therapies - Panel Discussion, Todd McAllister, PhD., Francesca Vitelli, PhD. and Warren Sherman, MD


Adipose Derived Stem Cells in Degenerative Diseases, Kristin Comella 


The Role of Platelet Rich Plasma in Adjuvant Wound Care - Clinical Experience Case Series, Ravi K. Kamepalli, M.D


Stem Cells and Orthopedic Conditions, Christopher Centeno, M.D. 

logo2 3

Latest Research - Adipose

Mesenchymal Stem Cells (MSC) are arising as a potent therapeutic tool in transplantation due to their regenerative and immunomodulatory properties. The research on MSCs has mainly focused on their effects on T cells and although data regarding the modulatory effects of MSCs on alloantigen-specific humoral response in humans is scarce, it has been demonstrated that MSCs significantly affect B cell functioning.


Endogenous progenitor cell mobilization enhances LD fat neovascularization, increases vasculogenic cytokine expression, and improves graft survival to a level equal to HD fat grafts.


Examination and comparison ofimmunomodulatory function of CP-MSCs with that of BM-MSCs and AD-MSCs using co-culture system with activated T-cells derived from human umbilical cord blood (UCB) suggest that while CP-MSCs, BM-MSCs, and AD-MSCs all have immunomodulatory effects, CP-MSCs may have additional advantage over the other MSCs in terms of immunomodulation. In conjunction with other previous studies, CP-MSCs are suggested to be a useful stem cell source in cell therapy.


Study to investigate the effect of long-term culture on the adipogenic, stemness and osteogenic genes expression during osteogenic induction of ASCs. In this study, the molecular characteristics of ASCs during osteogenic induction in long-term culture was analysed by observing their morphological changes during induction, analysis of cell mineralization using Alizarin Red staining and gene expression changes using quantitative RT-PCR.


Study on the effective expansion of human adipose-derived stromal cells and bone marrow-derived mesenchymal stem cells cultured on a fragmin/protamine nanoparticles-coated substratum with human platelet-rich plasma.


ASC-enriched lipofilling theoretically has the potential for transforming lipofilling from a relatively unpredictable intervention into one in which the resorption rate, quality of tissue, and safety can be predicted, and possibly superior to prosthetic implantation.

Currents in Cell Medicine is a monthly publication from the ICMS. 


To comment on articles, or suggest items for this newsletter, please contact the ICMS at 

Stem Cells in the NEWS

Oakland Raiders Linebacker Rolando McClain told the Mobile (Ala.) Press-Register that he has undergone stem-cell therapy for a sore knee and ankle. “I've been having two seasons of nagging pain in my knee,” McClain said. A radiologist in Gulf Shores, Ala., performed liposuction on McClain, then injected the LB's fat cells into McClain's knee and ankle. “It feels a lot better,” McClain said.


Researchers at Columbia University Medical Center (CUMC) have identified a molecular pathway that controls the retention and release of the brain’s stem cells.


Every year, more than a million Americans receive an artificial hip or knee prosthesis. To help minimize these burdensome operations, a team of MIT chemical engineers has developed a new stem cell-based coating for implants that could help them better adhere to the patient’s bone, preventing premature failure.

Baxter has commenced a new phase III clinical trial of a new stem cell-based treatment option for chronic myocardial ischemia (CMI).

In a case involving a criminal investigation into the recent death of a 77-year-old man after stem cell treatment, state health authorities say Dr. Zannos Grekos extracted tissue from the patient while a second doctor later injected the patient with his own concentrated stem cells. 


Please join Med Pro at the ICMS member reception immediately following the 4th Annual Congress to hear a special talk on Healthcare & Medical Tourism Marketing by internationally recognized marketing expert Patrick Goodness, CEO of the Goodness Company. The talk will center on the importance of social media, public relations, website marketing, video marketing and more.  Additionally, Patrick will discuss information on the importance of marketing in compliance with FTC regulations.

This special lecture, sponsored by Med Pro, will be open to all attendees of the ICMS Conference. Please join us at 6:30 PM on Thursday, May 3rd.

Latest Stem Cell Research

Study describes the effect of increased expression of HO-1 protein and increased levels of HO activity on differentiation of bone-marrow-derived human MSCs. MSCs are multipotent cells that proliferate and differentiate into many different cell types including adipocytes and osteoblasts.


Japanese researchers have successfully grown hair on hairless mice by implanting follicles created from stem cells, they announced Wednesday, sparking new hopes of a cure for baldness.


New findings in breast cancer research by an international team of scientists contradict the prevailing belief that only basal-like cells with stem cell qualities can form invasive tumors.


Researchers at the University of Colorado School of Medicine have found that lack of a specific gene interrupts neural tube closure, a condition that can cause death or paralysis.


MSCs are an ideal candidate cell type as building blocks for tissue engineering efforts to regenerate replacement tissues and repair damaged structures as encountered in various arthritic conditions. Osteoarthritis (OA) is the most common arthritic condition and, like rheumatoid arthritis (RA), presents an inflammatory environment with immunological involvement and this has been an enduring obstacle that can potentially limit the use of cartilage tissue engineering. Recent advances in our understanding of the functions of MSCs have shown that MSCs also possess potent immunosuppression and anti-inflammation effects.


Immunosuppressive properties of mesenchymal stem cells: advances and applications. 


MSC are immunosuppressive and poorly immunogenic and these features make them attractive candidates as therapeutic agents for diseases characterized by abnormal activation of the immune system, such as graft versus host disease (GVHD) and autoimmune disorders.

logo2 3

Tel: 503.877.1045
         Fax: 877.900.7273

Click here to forward this email to a friend

Try Email Marketing with VerticalResponse!